GS-US-337-1118: An Open-Label, Multicenter Study To Evaluate The Efficacy And Safety Of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin For 12 or 24 Weeks In Chronic Genotype 1 HCV Infected Subjects Who Participated In A Prior Gilead-Sponsored HC

Project: Research project

Project Details

StatusFinished
Effective start/end date3/4/143/4/17

Funding

  • PRA Health Sciences (GS-US-337-1118)
  • Gilead Sciences, Inc. (GS-US-337-1118)